Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA_1c:a meta-analysis of published randomized clinical trials

References

• International Diabetes Federation. The global burden of diabetes. In: Gan D, editor. Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2003. p. 15–78
   Google Scholar
• Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes. Diabetes Care 2005;28:2130–5
   PubMed Web of Science ®Google Scholar
• Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004;44:397–405
   PubMed Web of Science ®Google Scholar
• Clark Jr MJ, Sterrett JJ, Stier Carson D. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 2000;22:899–910
   Google Scholar
• American Diabetes Association. Clinical practice recommendations 2000. Diabetes Care 2000;23(Suppl 1):S1–S116
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Stratton IM, Adler AI, Neil AW, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Avendia® (rosiglitazone maleate) tablets. AV: LXX prescribing information. NDA 21–071/S-015 2005. Available from: URL: www.fda.gov/cder/foi/label/2005/ 021071s015lbl.pdf [last accessed August 24, 2006]
   Google Scholar
• Takeda American Research and Development Center. Actos TM (Pioglitazone Hydrochloride) tablets. NDA No 21–073 1999:1–26. Available from: URL: www.fda.gov/cder/foi/label/ 2004/21073s023lbl.pdf [last accessed August 24, 2006]
   Google Scholar
• Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control? Curr Med Res Opin 2003;19:192–9
   PubMed Web of Science ®Google Scholar
• Sutton AJ, Abrams KR, Jones DB, et al. Systematic reviews of trials and other studies. Health Technol Assess 1998;2:1–276
   PubMedGoogle Scholar
• Johansen K. Efficacy of metformin in the treatment of NIDDM. Diabetes Care 1999;22:33–7
   PubMed Web of Science ®Google Scholar
• Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando: Academic Press; 1985
   Google Scholar
• Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005;54:24–32
   PubMed Web of Science ®Google Scholar
• Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24: 308–15
   PubMed Web of Science ®Google Scholar
• Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1: 165–72
   Google Scholar
• Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000;43:278–84
   PubMed Web of Science ®Google Scholar
• Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280–8
   PubMed Web of Science ®Google Scholar
• St John SM, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058–64
   PubMed Web of Science ®Google Scholar
• Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;67:43–52
   PubMed Web of Science ®Google Scholar
• Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27:1349–57
   PubMed Web of Science ®Google Scholar
• Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002;51:3479–85
   PubMed Web of Science ®Google Scholar
• Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res 2002;10:1008–15
   PubMedGoogle Scholar
• Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004;147:e23
   Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study [The Pioglitazone 001 Study Group]. Diabetes Care 2000;23:1605–11
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413–23
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068–76
   PubMed Web of Science ®Google Scholar
• Goke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002;1:329–36
   PubMedGoogle Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547–54
   PubMed Web of Science ®Google Scholar
• Yamanouchi T, Sakai T, Igarashi K, et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabetic Med 2005;22:980–5
   PubMed Web of Science ®Google Scholar
• Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004;27:41–6
   PubMed Web of Science ®Google Scholar
• Weisman PW, Goldstein BJ, Campbell JC, et al. Rosiglitazone plus metformin combination effects on CV risk markers suggest potential CV benefits in type 2 diabetes patients. Diabetes [ADA] 2004;53:2 [abstract A28]
   Google Scholar
• Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized double-blind, parallel-group study. Clin Ther 2005;27:1548–60
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabetic Med 2000;17:40–7
   PubMed Web of Science ®Google Scholar
• Raskin P, McGill J, Saad MF, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabetic Med 2004;21:329–35
   PubMed Web of Science ®Google Scholar
• Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226–32
   PubMed Web of Science ®Google Scholar
• Kerenyi Z, Samer H, James R, et al. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004;63:213–23
   PubMed Web of Science ®Google Scholar
• Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003;5:163–70
   PubMed Web of Science ®Google Scholar
• Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol 2004;41:63–9
   PubMed Web of Science ®Google Scholar
• Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002;18:456–61
   PubMed Web of Science ®Google Scholar
• Zhu XX, Pan CY, Li GW, et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther 2003;5:33–42
   PubMedGoogle Scholar
• Barnett AH, Grant PJ, Hitman GA, et al. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabetic Med 2003;20:387–93
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled parallel-group trial. Clin Ther 2004;26:744–54
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251–7
   PubMed Web of Science ®Google Scholar
• Matthews DR, Charbonnel BH, Hanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167–74
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141–7
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004;63:127–34
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10–7
   PubMed Web of Science ®Google Scholar
• Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with Type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005;27:554–67
   PubMed Web of Science ®Google Scholar
• Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493–9
   PubMed Web of Science ®Google Scholar
• Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabetic Med 2004;21:136–41
   PubMed Web of Science ®Google Scholar
• Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 200415;116: 230–5
   Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24: 710–9
   PubMed Web of Science ®Google Scholar
• McMohan GT, Plutzky J, Daher E, et al. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care 2005;28:1145–50
   PubMed Web of Science ®Google Scholar
• Gomez-Perez FJ, Fanghanel-Salmon G, Antonio BJ, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127–34
   PubMed Web of Science ®Google Scholar
• Orbay E, Sargin M, Sargin H, et al. Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes. Endocr J 2004;51:521–7
   PubMed Web of Science ®Google Scholar
• Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074–95
   PubMed Web of Science ®Google Scholar
• Davidson JA, Perez A, Zhang J, and the Pioglitazone 343 study group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicenter, randomized study. Diabetes Obes Metab 2005;1–11
   Google Scholar
• Marre M, Van Gaal L, Usadel K-H, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002;4: 177–86
   Google Scholar
• Horton ES, Clinkingbeard C, Galtin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660–5
   PubMed Web of Science ®Google Scholar
• Garber AJ, Donovan DS, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial mono-therapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88: 3598–604
   PubMed Web of Science ®Google Scholar
• Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995;11:S57–S62
   PubMed Web of Science ®Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000;283:1695–702
   PubMed Web of Science ®Google Scholar